Temporal changes in dialysate [Na] prescription from 1996 to 2018 and their clinical significance as judged from a meta-regression of clinical trials.

Over the last two decades, the clinical care of dialysis patients has refocused sharply on fluid volume control. Dialysate [Na] is a key, albeit under-investigated, clinical tool for manipulation of fluid volume on dialysis. In the article, we firstly use data from the Dialysis Outcomes and Practice Patterns Study to document the global decrease in dialysate [Na] that has occurred from 1996 to 2018, and demonstrate the virtual disappearance of [Na] profiling from routine dialysis practice over the same period. Second, we used data from previously synthesized randomized clinical trial evidence combined with that of a more recently published trail to assess the clinical significance of these changes, estimating the effects of different levels of low dialysate [Na] on key clinical outcomes. Our analyses suggest that current levels of dialysate [Na] in some health jurisdictions are possibly causing harm to many patients, especially given that real world populations are significantly less robust and more vulnerable than clinical trial ones. To quote a recent editorial, "more evidence needed before lower dialysate sodium concentrations can be recommended." That evidence is coming, and no further changes should be made to default customary practice until it is available.

© 2020 Wiley Periodicals LLC.